In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma

Bas D. Koster, Tamarah D. de Jong, Mari F.C.M. van den Hout, Berbel J.R. Sluijter, Ronald J.C.L.M. Vuylsteke, Barbara G. Molenkamp, Saskia Vosslamber, M. Petrousjka van den Tol, Alfons J.M. van den Eertwegh, Tanja D. de Gruijl*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences.

Original languageEnglish
Article number1708066
JournalOncoImmunology
Volume9
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Cite this